Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis C

  Free Subscription


18.04.2017

1 Eur J Gastroenterol Hepatol
1 Gastroenterology
2 Hepatology
2 J Hepatol
1 J Infect Dis
2 J Med Virol
1 J Virol
21 Lancet Gastroenterol Hepatol
5 PLoS One
1 Proc Natl Acad Sci U S A
1 Transplant Proc
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Eur J Gastroenterol Hepatol

  1. TABERNILLA A, Grandal M, Pernas B, Castro-Iglesias A, et al
    Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Eur J Gastroenterol Hepatol. 2017 Apr 13. doi: 10.1097/MEG.0000000000000882.
    PubMed     Text format     Abstract available


    Gastroenterology

  2. JACOBSON IM, Lawitz E, Gane EJ, Willems BE, et al
    Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Gastroenterology. 2017 Apr 5. pii: S0016-5085(17)35399.
    PubMed     Text format     Abstract available


    Hepatology

  3. GUO X, Wang S, Qiu ZG, Dou YL, et al
    Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29211.
    PubMed     Text format     Abstract available

  4. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    PubMed     Text format    


    J Hepatol

  5. LANGHANS B
    Reply to "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".
    J Hepatol. 2017 Apr 9. pii: S0168-8278(17)30205.
    PubMed     Text format    

  6. SCHWARZINGER M, Baillot S, Yazdanpanah PY, Rehm PJ, et al
    Contribution of Alcohol Use Disorders on the Burden of Chronic Hepatitis C in France, 2008-2013: A Nationwide Retrospective Cohort Study.
    J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30202.
    PubMed     Text format     Abstract available


    J Infect Dis

  7. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Med Virol

  8. DE PASCHALE M, Manco MT, Arpino O, Ricucci V, et al
    Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24831.
    PubMed     Text format     Abstract available

  9. JIAO X, Fan Z, Chen H, He P, et al
    Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24829.
    PubMed     Text format     Abstract available


    J Virol

  10. FAN H, Qiao L, Kang KD, Fan J, et al
    Attachment and Post-Attachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.
    J Virol. 2017 Apr 12. pii: JVI.00280-17. doi: 10.1128/JVI.00280.
    PubMed     Text format     Abstract available


    Lancet Gastroenterol Hepatol

  11. ROCKSTROH JK, Bhagani S, Hyland RH, Yun C, et al
    Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
    Lancet Gastroenterol Hepatol. 2017;2:347-353.
    PubMed     Text format     Abstract available


  12. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    Lancet Gastroenterol Hepatol. 2017;2:325-336.
    PubMed     Text format     Abstract available

  13. MARTINELLO M, Grebely J, Matthews GV
    Direct-acting antivirals for acute HCV: how short can we go?
    Lancet Gastroenterol Hepatol. 2017;2:316-318.
    PubMed     Text format    

  14. DUSHEIKO G
    Hepatitis C in the EU: setting the terms for elimination.
    Lancet Gastroenterol Hepatol. 2017;2:314-315.
    PubMed     Text format    

  15. HAJARIZADEH B, Grebely J, Martinello M, Matthews GV, et al
    Hepatitis C treatment as prevention: evidence, feasibility, and challenges.
    Lancet Gastroenterol Hepatol. 2016;1:317-327.
    PubMed     Text format     Abstract available

  16. DEBES JD, Janssen HL, Boonstra A
    Hepatitis C treatment and liver cancer recurrence: cause for concern?
    Lancet Gastroenterol Hepatol. 2017;2:78-80.
    PubMed     Text format    

  17. THE LANCET GASTROENTEROLOGY HE
    Access to HCV treatments: hurdles not barriers.
    Lancet Gastroenterol Hepatol. 2017;2:1.
    PubMed     Text format    

  18. ISLAM N, Krajden M, Shoveller J, Gustafson P, et al
    Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
    Lancet Gastroenterol Hepatol. 2017;2:200-210.
    PubMed     Text format     Abstract available


  19. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
    Lancet Gastroenterol Hepatol. 2017;2:161-176.
    PubMed     Text format     Abstract available

  20. COOPER S, Umeweni N, Knight H, McVeigh G, et al
    Sofosbuvir-velpatasvir for treating chronic hepatitis C.
    Lancet Gastroenterol Hepatol. 2017;2:156-157.
    PubMed     Text format    

  21. INGILIZ P, Rockstroh JK
    Hepatitis C virus reinfection-more to come?
    Lancet Gastroenterol Hepatol. 2017;2:150-151.
    PubMed     Text format    

  22. FOSTER GR
    Chronic hepatitis C: less of a problem than first thought?
    Lancet Gastroenterol Hepatol. 2017;2:146-147.
    PubMed     Text format    

  23. WAKED I, Shiha G, Qaqish RB, Esmat G, et al
    Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
    Lancet Gastroenterol Hepatol. 2016;1:36-44.
    PubMed     Text format     Abstract available

  24. RYDER S, Pett S, Cooke GS
    Genotype 4 and the global challenge of hepatitis C treatment.
    Lancet Gastroenterol Hepatol. 2016;1:3-4.
    PubMed     Text format    

  25. ASSELAH T, Hezode C, Qaqish RB, ElKhashab M, et al
    Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
    Lancet Gastroenterol Hepatol. 2016;1:25-35.
    PubMed     Text format     Abstract available

  26. LIM SG, Aghemo A, Chen PJ, Dan YY, et al
    Management of hepatitis C virus infection in the Asia-Pacific region: an update.
    Lancet Gastroenterol Hepatol. 2017;2:52-62.
    PubMed     Text format     Abstract available

  27. YOUNOSSI ZM, Stepanova M, Charlton M, Curry MP, et al
    Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Lancet Gastroenterol Hepatol. 2016;1:122-132.
    PubMed     Text format     Abstract available

  28. COILLY A, Roche B, Duclos-Vallee JC, Samuel D, et al
    Optimum timing of treatment for hepatitis C infection relative to liver transplantation.
    Lancet Gastroenterol Hepatol. 2016;1:165-172.
    PubMed     Text format     Abstract available

  29. CORNBERG M, Manns MP
    Hepatitis C: individualised medicine versus one pill fits all.
    Lancet Gastroenterol Hepatol. 2016;1:86-87.
    PubMed     Text format    

  30. BUTI M, Esteban R
    Patient experience in HCV therapy: what really matters.
    Lancet Gastroenterol Hepatol. 2016;1:90-92.
    PubMed     Text format    

  31. WAIT S, Kell E, Hamid S, Muljono DH, et al
    Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments.
    Lancet Gastroenterol Hepatol. 2016;1:248-255.
    PubMed     Text format     Abstract available


    PLoS One

  32. YASUI Y, Abe T, Kurosaki M, Higuchi M, et al
    Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0154558.
    PubMed     Text format     Abstract available

  33. LE GUILLOU-GUILLEMETTE H, Pivert A, Bouthry E, Henquell C, et al
    Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.
    PLoS One. 2017;12:e0174651.
    PubMed     Text format     Abstract available

  34. FERNANDEZ-CABALLERO JA, Alvarez M, Chueca N, Perez AB, et al
    The cobas(R) HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice.
    PLoS One. 2017;12:e0175564.
    PubMed     Text format     Abstract available

  35. YANG CM, Yoon JC, Park JH, Lee JM, et al
    Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
    PLoS One. 2017;12:e0175793.
    PubMed     Text format     Abstract available

  36. CHLIBEK R, Smetana J, Sosovickova R, Gal P, et al
    Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.
    PLoS One. 2017;12:e0175525.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  37. HANSEN MD, Johnsen IB, Stiberg KA, Sherstova T, et al
    Hepatitis C virus triggers Golgi fragmentation and autophagy through the immunity-related GTPase M.
    Proc Natl Acad Sci U S A. 2017 Apr 7. pii: 201616683.
    PubMed     Text format     Abstract available


    Transplant Proc

  38. SAFWAN M, Nagai S, Abouljoud MS
    Portal Vein Inflow From Enlarged Coronary Vein in Liver Transplantation: Surgical Approach and Technical Tips: A Case Report.
    Transplant Proc. 2016;48:3070-3072.
    PubMed     Text format     Abstract available


    Virology

  39. EYRE NS, Aloia AL, Joyce MA, Chulanetra M, et al
    Sensitive luminescent reporter viruses reveal appreciable release of hepatitis C virus NS5A protein into the extracellular environment.
    Virology. 2017;507:20-31.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: